Sunitinib malate for the treatment of renal cell carcinoma
Author:
- 21 May 2012
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 13 (9) , 1323-1336
Abstract
Introduction: Over the past decade, a greater understanding into the molecular pathogenesis of renal cell carcinoma (RCC) has led to major advances in treatment options. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor (TKI) that targets a number of receptors, including vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR). Sunitinib was one of the first targeted agents studied in metastatic RCC (mRCC) and is currently used worldwide in the management of mRCC. Areas covered: This drug evaluation addresses the preclinical and clinical development of sunitinib. It provides an in-depth discussion of the Phase II data that led to its approval in mRCC and the subsequent Phase III clinical trial comparing sunitinib to interferon-α. More recent data from the large international expanded access trial, in non-clear cell carcinoma patients, different dosing schedule studies and safety issues are also discussed. Finally, areas...Keywords
This publication has 44 references indexed in Scilit:
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemotherapy and Pharmacology, 2009
- Sunitinib Efficacy Against Advanced Renal Cell CarcinomaJournal of Urology, 2007
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood, 2005
- Role ofVHLGene Mutation in Human CancerJournal of Clinical Oncology, 2004
- The Genetic Basis of Cancer of the KidneyJournal of Urology, 2003
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and TherapyJournal of Clinical Oncology, 2002
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993